226 related articles for article (PubMed ID: 34956082)
21. Bone morphogenetic protein signaling in prostate cancer cell lines.
Brubaker KD; Corey E; Brown LG; Vessella RL
J Cell Biochem; 2004 Jan; 91(1):151-60. PubMed ID: 14689587
[TBL] [Abstract][Full Text] [Related]
22. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
Lai TH; Fong YC; Fu WM; Yang RS; Tang CH
Prostate; 2008 Sep; 68(12):1341-53. PubMed ID: 18512729
[TBL] [Abstract][Full Text] [Related]
23. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer.
Bobinac D; Marić I; Zoricić S; Spanjol J; Dordević G; Mustać E; Fuckar Z
Croat Med J; 2005 Jun; 46(3):389-96. PubMed ID: 15861517
[TBL] [Abstract][Full Text] [Related]
24. Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study.
Spanjol J; Djordjević G; Markić D; Klarić M; Fuckar D; Bobinac D
Coll Antropol; 2010 Apr; 34 Suppl 2():119-25. PubMed ID: 21302710
[TBL] [Abstract][Full Text] [Related]
25. BMP4 promotes prostate tumor growth in bone through osteogenesis.
Lee YC; Cheng CJ; Bilen MA; Lu JF; Satcher RL; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
Cancer Res; 2011 Aug; 71(15):5194-203. PubMed ID: 21670081
[TBL] [Abstract][Full Text] [Related]
26. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
27. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
[TBL] [Abstract][Full Text] [Related]
28. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
Miyazaki H; Watabe T; Kitamura T; Miyazono K
Oncogene; 2004 Dec; 23(58):9326-35. PubMed ID: 15531927
[TBL] [Abstract][Full Text] [Related]
29. Dorsomorphin homologue 1, a highly selective small-molecule bone morphogenetic protein inhibitor, suppresses medial artery calcification.
Lin T; Wang XL; Zettervall SL; Cai Y; Guzman RJ
J Vasc Surg; 2017 Aug; 66(2):586-593. PubMed ID: 27374065
[TBL] [Abstract][Full Text] [Related]
30. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.
Buijs JT; Rentsch CA; van der Horst G; van Overveld PG; Wetterwald A; Schwaninger R; Henriquez NV; Ten Dijke P; Borovecki F; Markwalder R; Thalmann GN; Papapoulos SE; Pelger RC; Vukicevic S; Cecchini MG; Löwik CW; van der Pluijm G
Am J Pathol; 2007 Sep; 171(3):1047-57. PubMed ID: 17724140
[TBL] [Abstract][Full Text] [Related]
31. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
Bhatia V; Saini MK; Shen X; Bi LX; Qiu S; Weigel NL; Falzon M
Mol Cancer Ther; 2009 Jul; 8(7):1787-98. PubMed ID: 19584236
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals.
Nishimori H; Ehata S; Suzuki HI; Katsuno Y; Miyazono K
J Biol Chem; 2012 Jun; 287(24):20037-46. PubMed ID: 22532569
[TBL] [Abstract][Full Text] [Related]
33. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
Al Nakouzi N; Bawa O; Le Pape A; Lerondel S; Gaudin C; Opolon P; Gonin P; Fizazi K; Chauchereau A
Neoplasia; 2012 May; 14(5):376-87. PubMed ID: 22745584
[TBL] [Abstract][Full Text] [Related]
34. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Eixarch H; Calvo-Barreiro L; Costa C; Reverter-Vives G; Castillo M; Gil V; Del Río JA; Montalban X; Espejo C
Neurotherapeutics; 2020 Oct; 17(4):1988-2003. PubMed ID: 32681355
[TBL] [Abstract][Full Text] [Related]
37. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
Lee GT; Kang DI; Ha YS; Jung YS; Chung J; Min K; Kim TH; Moon KH; Chung JM; Lee DH; Kim WJ; Kim IY
Br J Cancer; 2014 Mar; 110(6):1634-44. PubMed ID: 24518599
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
[TBL] [Abstract][Full Text] [Related]
40. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
